Commentary about open-label randomized controlled study of ivermectin in mild to moderate COVID-19

Authors

  • Giovanni Meneses Departamento Académico de Medicina Preventivay Salud Pública, Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Peru

Keywords:

ivermectin, COVID-19

Abstract

Abstract not available

Ibrahim Med. Coll. J. 2020; 14(2): 67-68

Abstract
0
PDF
0

Downloads

Published

2021-04-05

How to Cite

Commentary about open-label randomized controlled study of ivermectin in mild to moderate COVID-19. (2021). IMC Journal of Medical Science, 14(2), 67-68. https://doi.org/10.3329/imcjms.v14i2.52833

Issue

Vol. 14 No. 2 (2020)

Section

Letters to the Editor

License

Authors who publish in IMCJMS agree to the following terms that:

  1. Authors retain copyright and grant IMCJMS the right of first publication of the work.

  2. Creative Commons Licence
    Articles in IMCJMS are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.

How to Cite

Commentary about open-label randomized controlled study of ivermectin in mild to moderate COVID-19. (2021). IMC Journal of Medical Science, 14(2), 67-68. https://doi.org/10.3329/imcjms.v14i2.52833